HC Wainwright & Co. Reiterates Buy on Theseus Pharmaceuticals, Maintains $22 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Andrew Fein reiterated a Buy rating on Theseus Pharmaceuticals (NASDAQ:THRX) and maintained a $22 price target.
May 26, 2023 | 10:20 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
HC Wainwright & Co. analyst Andrew Fein reiterated a Buy rating on Theseus Pharmaceuticals (NASDAQ:THRX) and maintained a $22 price target.
The reiteration of a Buy rating and maintenance of a $22 price target by HC Wainwright & Co. analyst Andrew Fein indicates a positive outlook for Theseus Pharmaceuticals. This news is likely to have a positive short-term impact on the stock price as it shows confidence in the company's potential.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100